(d)           On November 27, 2007, our Board of Directors appointed Anthony E. Altig as a director. Mr Altig was also appointed as a member of the Audit Committee and the Nominating and Corporate Governance Committee.

                From December 2004 to June 2007, Mr. Altig served as the Senior Vice President, Finance, Chief Financial Officer, and Secretary of Diversa Corporation (subsequently Verenium Corporation), a public company developing specialized industrial enzymes. Prior to joining Diversa, Mr. Altig served as the Chief Financial Officer of Maxim Pharmaceuticals, a public biopharmaceutical company, from 2002 to 2004. In addition to these and other corporate positions, Mr. Altig served as a consultant to the biotechnology and technology industry during his tenure at both PricewaterhouseCoopers and KPMG. In addition, Mr. Altig serves as a director and chair of the Audit Committee for MultiCell Technologies, a public biopharmaceutical company.